You just read:

Actinium Launches Iomab-ACT Program Offering Its Targeted, Chemo-Free, Lymphodepletion Technology as a Universal Solution to CAR-T Product Developers

News provided by

Actinium Pharmaceuticals, Inc.

Oct 01, 2018, 08:00 ET